Protein A Agarose Beads / Resin | 重组蛋白 A 琼脂糖纯化树脂价格

保存条件：在-20℃ to -80℃

保质期：12个月

英文名：Protein A Agarose Beads / Resin

库存：99

供应商：北京义翘神州科技股份有限公司

规格：1 mL/5 mL/10 mL/25 mL/50 mL

Introduction

Sino Biological Protein A Agarose Beads / Resin was produced by immobilizing recombinant protein A to 4% cross-linked agarose matrix. The recombinant protein A contains IgG binding domains, eliminating nonspecific binding sites and reducing steric hindrance.

Specifications

Ligand	Recombinant protein A
Dynamic binding capacity	~30 mg human IgG/ml drained medium
Matrix	4% highly cross-linked agarose
Bead size	45–165 μm
Mean bead size	90 μm
Maximum linear flow rate	>150 cm/h
pH stability	Long term:3-9 Short term: 2-10 Working: 2-9
Sanitization	Sanitize the packed column with 2% Hibitane/20% ethanol or with 70% ethanol
Storage	+4–8 °C in 20% ethanol
Package	1ml, 5ml, 10ml, 25ml, 50ml, Bulk

Experiment:

Column:	5x 45 mm, bed volume 0.9 ml
Resin:	Protein A agarose resin
Binding Buffer:	50 mM Tris, 100 mM NaCl, pH 8.0
Elution Buffer:	100 mM glycin, 10 mM NaCl, pH 3.0
Sample:	Human IgG, 2.2 mg/ml
Flow Rate:	0.3 ml/min
Procedure:	The column was equilibrated with biding buffer, then apply the sample at fow rate of 0.3 ml/min, when the flowthrough concentration reach 0.22 mg/min stop loading and wash the columm with biding buffer, when asorbency of 280 nm decrease to base line, elute with elution buffer.
Result:	26.7 mg human IgG was recovered in eluant, Dynamic binding capacity of the colun is about 29.7 mg/ml

Chromatography graph of measuring dynamic binding capacity

Repeated Cycle Usage

Repeated usage in practical manufacturing: The feedstock used was the supernatant of 293 cell line expressing various humanized monocolnal antibody, human monoclonal antibody or protein-Fc chimera. The volume of culture varies from 1000ml to 2000ml.
Column:	bed volumn of 20 ml with dimention of 26x 100 m
Flow rate:	7 ml/min
Binding buffer	50 mM Tris, 100 mM NaCl, pH 8.0
Elution buffer	100 mM glycerin, 10 mM NaCl, pH 3.0
CIP buffer:	50 mM NaOH, 1 M NaCl
Purification cycle	• 5 cv binding buffer wash the column • 5 cv elution buffer • 2 cv binding buffer • 3 cv CIP buffer • 3 cv binding buffer
Measure column capacity:	Comlumn capacity was tested every 15 practical purification cycle by applying 600 mg of a humanized monoclonal antibody with concentration of 1 mg/ml, and measure the recovery of the antibody. The procedure is the same with purification cycle. All capacity test experiment use the same antibody.

CIP Protocol

The most common CIP procedure for Protein A resin is washing the resin with 2 column volumes of 6 M guanidine hydrochloride to remove precipitated or denatured substances, followed by re-equilibrating with at least 5 column volumes of binding buffer.

For strongly bound hydrophobic proteins, lipoproteins and lipids, wash the resin with a non-ionic detergent, for instance, 0.1%. Triton X-100, at 37 °C. Immediately re-equilibrate with at least 5 column volumes of binding buffer.

If the above methods are still not effective to remove the impurities, wash the medium with 5 column volumes of 50 mM NaOH, 1 M NaCl solution, Re-equilibrate with at least 5 column volumes of binding buffer.

Protein A residual

Protein A residual in 10 monoclonal antibodies randomly taken from manufactural purification. The feedstock used was the supernatant of 293 cell line expressing various humanized monocolnal antibody, human monoclonal antibody or protein-Fc chimera. The volume of culture loaded varies from 1000 ml to 2000 ml.

Stability Study

The IgG binding capacity and recovery was maintained after seven days storage at room temperature in solutions list below:
3 M NaSCN
6 M guanidine-HCl
8 M urea
0.1 M glycine, pH 3.0
70% ethanol.

Recovery of antibody at the loading burden of 30 mg/ml medium after storage in varous solutions.

Column Regeneration

Regeneration step should be operated after elution to remove the residue proteins and impurities on the resin for repeated use. Wash the resin with 2–3 bed volumes of regeneration buffer followed by re-equilibration with 2–3 bed volumes of binding buffer. Sometimes the regeneration buffer is the same with the elution buffer, such as 0.1 M glycine buffer pH 3.0 or 0.1 M citric acid pH 3.0. When the elution buffer has a milder condition to avoid aggregation or degradation, the regeneration buffer is different, with a lower pH or containing different salts. But this procedure does not guarantee removing all kinds of impurities like denatured proteins or lipids. In this case, cleaning in place procedure is indispensable.

Storage

For storage, keep the medium at 2°C to 8°C in a suitable bacteriostat, e.g. 20% ethanol and/or 0.02% sodium azide. Notice: The resin must not be frozen.

IgG binding of protein A, G, and L

Strong binding ＋＋, medium interaction ＋, weak or no interaction －.

该产品被引用文献

1, Teng, Q; et al. Mutagenesis of the di-leucine motif in the cytoplasmic tail of newcastle disease virus fusion protein modulates the viral fusion ability and pathogenesis. Virology journal, Pubmed: 36759854
2, Jeong, BS; et al. Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants. mAbs, Pubmed: 35030983
3, Song, J; et al. Noncovalent antibody catenation on a target surface greatly increases the antigen-binding avidity. eLife, Pubmed: 37249578
4, Nadal, L; et al. Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody. Journal for immunotherapy of cancer, Pubmed: 36104101
5, Bujak, E; et al. Monoclonal antibodies to murine thrombospondin-1 and thrombospondin-2 reveal differential expression patterns in cancer and low antigen expression in normal tissues. Exp. Cell Res., Pubmed: 24925479
6, Akkapeddi, P; et al. A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia. Leukemia, Pubmed: 30850736
7, Li, M; et al. Sirt3 modulates fatty acid oxidation and attenuates cisplatin-induced AKI in mice. J. Cell. Mol. Med., Pubmed: 32281286
8, Millul, J; et al. Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX. bioRxiv
9, E Bujak, M Matasci, D Neri, S Wulhfard. Reformatting of scFv Antibodies into the scFv-Fc Format and Their Downstream Purification. Methods in Molecular Biology, Pubmed: 24515475
10, Leong, ML. An inducible and reversible genetics platform for novel drug target discovery. Thesis